Feature Review Paper Special Issue in Section Molecular Cancer Biology

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".

Deadline for manuscript submissions: 30 September 2025 | Viewed by 2654

Special Issue Editor


E-Mail Website
Guest Editor
Experimental Neurosurgery, Neuroscience Center, Goethe-University Frankfurt, Theodor-Stern-Kai 7, D-60590 Frankfurt am Main, Germany
Interests: brain tumors; intrinsic and acquired therapy resistance; apoptosis; autophagy; mitochondria as targets for cancer therapy; mechanisms of tumor cell migration and invasion
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The Section “Molecular Cancer Biology” covers all aspects of molecular and cellular biology related to the development, progression and therapy of cancer. We are pleased to announce this Special Issue, to which I would like to invite you to contribute a paper. In this Special Issue, reviews and systematic reviews focusing on the most significant developments and the current progress in this area of research will be included. We welcome the submission of manuscripts related to all topics of interest, as listed below.

The topics of interest include the following:

  • Oncogenesis and cancer progression;
  • Cancer immunology and immunotherapy;
  • Drug discovery and targeted therapy;
  • Gene therapy;
  • Tumor invasion and metastasis;
  • Cancer stem cell biology;
  • Genomic instability;
  • DNA damage and repair;
  • Cell cycle regulation;
  • Hypoxia;
  • Cancer cell metabolism;
  • Mechanisms of therapy resistance;
  • Autophagy;
  • Apoptosis;
  • Necrosis;
  • Senescence;
  • Angiogenesis;
  • Inflammation and cancer;
  • Epigenetics and cancer;
  • Molecular profiling of cancer.

Prof. Dr. Donat Kögel
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • molecular biology
  • cell biology
  • cancer
  • tumor
  • cancer cell

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Review

26 pages, 8774 KiB  
Review
RNA Binding Proteins as Potential Therapeutic Targets in Colorectal Cancer
by Vikash Singh, Amandeep Singh, Alvin John Liu, Serge Y. Fuchs, Arun K. Sharma and Vladimir S. Spiegelman
Cancers 2024, 16(20), 3502; https://doi.org/10.3390/cancers16203502 - 16 Oct 2024
Viewed by 1288
Abstract
RNA-binding proteins (RBPs) play critical roles in regulating post-transcriptional gene expression, managing processes such as mRNA splicing, stability, and translation. In normal intestine, RBPs maintain the tissue homeostasis, but when dysregulated, they can drive colorectal cancer (CRC) development and progression. Understanding the molecular [...] Read more.
RNA-binding proteins (RBPs) play critical roles in regulating post-transcriptional gene expression, managing processes such as mRNA splicing, stability, and translation. In normal intestine, RBPs maintain the tissue homeostasis, but when dysregulated, they can drive colorectal cancer (CRC) development and progression. Understanding the molecular mechanisms behind CRC is vital for developing novel therapeutic strategies, and RBPs are emerging as key players in this area. This review highlights the roles of several RBPs, including LIN28, IGF2BP1–3, Musashi, HuR, and CELF1, in CRC. These RBPs regulate key oncogenes and tumor suppressor genes by influencing mRNA stability and translation. While targeting RBPs poses challenges due to their complex interactions with mRNAs, recent advances in drug discovery have identified small molecule inhibitors that disrupt these interactions. These inhibitors, which target LIN28, IGF2BPs, Musashi, CELF1, and HuR, have shown promising results in preclinical studies. Their ability to modulate RBP activity presents a new therapeutic avenue for treating CRC. In conclusion, RBPs offer significant potential as therapeutic targets in CRC. Although technical challenges remain, ongoing research into the molecular mechanisms of RBPs and the development of selective, potent, and bioavailable inhibitors should lead to more effective treatments and improved outcomes in CRC. Full article
Show Figures

Figure 1

11 pages, 1597 KiB  
Review
Minimal Requirements for Cancer Initiation: A Comparative Consideration of Three Prototypes of Human Leukemia
by Toshiyuki Hori
Cancers 2024, 16(17), 3109; https://doi.org/10.3390/cancers16173109 - 9 Sep 2024
Viewed by 1187
Abstract
Even if its completed form is complex, cancer originates from one or two events that happened to a single cell. A simplified model can play a role in understanding how cancer initiates at the beginning. The pathophysiology of leukemia has been studied in [...] Read more.
Even if its completed form is complex, cancer originates from one or two events that happened to a single cell. A simplified model can play a role in understanding how cancer initiates at the beginning. The pathophysiology of leukemia has been studied in the most detailed manner among all human cancers. In this review, based on milestone papers and the latest research developments in hematology, acute promyelocytic leukemia (APL), chronic myeloid leukemia (CML), and acute myeloid leukemia (AML) with RUNX1-RUNX1T1 are selected to consider minimal requirements for cancer initiation. A one-hit model can be applied to the initiation of APL and CML whereas a two-hit model is more suitable to the initiation of AML with RUNX1-RUNX1T1 and other AMLs. Even in cancer cells with multiple genetic abnormalities, there must be a few mutant genes critical for the mutant clone to survive and proliferate. Such genes should be identified and characterized in each case in order to develop individualized target therapy. Full article
Show Figures

Figure 1

Back to TopTop